This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
RESMÉTIROM
INN: RESMÉTIROM
Data updated: 2026-04-11
Available in:
🇩🇪🇬🇧🇫🇷
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
MADRIGAL PHARMACEUTICALS EU (IRLANDE) (FR)
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Source
BDPM_FR
USDailyMed:Resmetirom
A05BA11(WHO)
US:℞-onlyEU:Rx-only
2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
920509-32-6
15981237
DB12914
RE0V0T1ES0
D11602
ChEMBL3261331
DTXSID601352610
Interactive image
CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)Key:FDBYIYFVSAHJLY-UHFFFAOYSA-N
Resmetirom, sold under the brand nameRezdiffra, is a medication used to treat a form offatty liver disease. Specifically it is used in the treatment of noncirrhoticmetabolic dysfunction associated steatohepatitis(MASH) (formerly known as nonalcoholic steatohepatitis NASH).It is structurally similar to thethyroid hormonetriiodothyronineand acts as anagonistof thethyroid hormone receptor beta(NR1A2).
The most common side effects include diarrhea and nausea.
Resmetirom was approved for medical use in the US in March 2024,and in the European Union in August 2025.The USFood and Drug Administrationconsiders it to be afirst-in-class medication.
